- Novan ( NASDAQ: NOVN ) has submitted a New Drug Application to the US FDA for berdazimer gel for the topical treatment of viral skin infection molluscum contagiosum.
- The submission is the first for the company.
- The application is supported by data from a phase 3 trial that showed highly statistically significant improvement in the primary clinical endpoint.
- Novan is down 13% in Friday morning trading.
- Novan ( NOVN ) is partnered with Ligand Pharmaceuticals ( NASDAQ: LGND ) on berdazimer.
- Seeking Alpha Quant Rating views Novan ( NOVN ) as a hold with strong marks for growth and revisions .
For further details see:
Novan submits NDA for berdazimer gel for viral skin infection